NIPPON INDIA PHARMA FUND holds 39 instruments (97.31% equity), led by Sun Pharmaceutical Industries Limited (11.71%), Divi's Laboratories Limited (7.1%) and Lupin Limited (6.17%), as of its 30 September 2026 SEBI-mandated monthly disclosure.
This page shows the complete disclosed portfolio of NIPPON INDIA PHARMA FUND, managed by Nippon India Mutual Fund, based on its monthly portfolio disclosure dated 30 September 2026. The fund holds 39 instruments with an equity allocation of 97.31%. Percentages are of net assets (% to NAV). Click any stock to see every other mutual fund that also holds it.
NIPPON INDIA PHARMA FUND's top 10 holdings account for 56.35% of its portfolio, more concentrated than the Thematic category average of 49.2%. Healthcare is its largest sector exposure at 94.78% of net assets, spread across 2 sectors in total. Since its 31 August 2026 disclosure, the fund added 0 new positions and exited 0 positions, with Sun Pharmaceutical Industries Limited seeing the largest move (-0.66pp to 11.71%).
Equity holdings grouped by sector, % to NAV. "Other" covers debt, cash and other non-equity instruments, plus any equity holding without a classified sector.
Equity holdings compared between the fund's two latest monthly disclosures. Weights are % to NAV; weight moves can also reflect price changes, not only buying or selling.
| Stock | Weight | Change |
|---|---|---|
| Dr. Reddy's Laboratories Limited | 4.93% → 5.45% | ▲ +0.52 |
| Mankind Pharma Limited | 4.09% → 4.38% | ▲ +0.29 |
| Abbott India Limited | 2.13% → 2.32% | ▲ +0.19 |
| Ajanta Pharma Limited | 3.47% → 3.61% | ▲ +0.14 |
| Dr. Lal Path Labs Ltd. | 2.04% → 2.17% | ▲ +0.13 |
| Suraksha Diagnostic Limited | 1.39% → 1.51% | ▲ +0.12 |
| Emcure Pharmaceuticals Limited | 1.25% → 1.36% | ▲ +0.11 |
| MOLBIO DIAGNOSTICS LTD | 0.44% → 0.54% | ▲ +0.1 |
| Akums Drugs and Pharmaceuticals Limited | 1.11% → 1.21% | ▲ +0.1 |
| Divi's Laboratories Limited | 7% → 7.1% | ▲ +0.1 |
| Stock | Weight | Change |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 12.37% → 11.71% | ▼ -0.66 |
| Apollo Hospitals Enterprise Limited | 5.15% → 4.89% | ▼ -0.26 |
| Lupin Limited | 6.43% → 6.17% | ▼ -0.26 |
| Pfizer Limited | 1.57% → 1.35% | ▼ -0.22 |
| Max Healthcare Institute Limited | 2.92% → 2.7% | ▼ -0.22 |
| Thyrocare Technologies Limited | 2.45% → 2.24% | ▼ -0.21 |
| GlaxoSmithKline Pharmaceuticals Limited | 3.31% → 3.11% | ▼ -0.2 |
| Fortis Healthcare Limited | 1.29% → 1.13% | ▼ -0.16 |
% to NAV of the fund's current top holdings over its last 6 monthly disclosures (Apr – Sept 2026).
New to reading these? See How to Read a Mutual Fund's Monthly Portfolio Disclosure, or check terms like % to NAV in the glossary.
Source: Nippon India Mutual Fund's SEBI-mandated monthly portfolio disclosure, dated 30 September 2026. Data is for information only, not investment advice. Holdings may have changed since the disclosure date.